文献速递泌尿男性生殖肿瘤

尿路上皮癌新型遗传亚型及其对免疫检查点阻断的差异化结局

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
PubMed 文献 · J Clin Oncol · 2023-03-16

研究对88例接受免疫检查点阻断(ICB)治疗的晚期膀胱癌患者肿瘤标本行全外显子测序,识别出与无进展生存和总生存相关的遗传因素,并定义四种分子亚型;在独立队列IMvigor210中验证了这四种亚型与ICB临床获益的关联,TCGA队列显示这些亚型在未接受ICB的患者中亦与结局相关但关系不同。

要点

  • ARID1A突变、肿瘤突变负荷、瘤内异质性、免疫肽组非同义/同义突变比值(immune dN/dS)和肿瘤细胞纯度与ICB后无进展生存和总生存相关。
  • 中性粒细胞与淋巴细胞比值和吸烟史与总生存呈负相关。
  • 这些遗传特征定义四种分子亚型,在IMvigor210队列中验证与ICB临床获益相关。

核心结论

  • 本研究定义了影响膀胱癌ICB获益的分子亚群。

研究设计与样本

  • 对88例接受ICB治疗的晚期膀胱癌患者肿瘤标本行全外显子测序。
  • 在独立队列IMvigor210中验证四种分子亚型与ICB临床获益的关联。
  • 利用癌症基因组图谱(TCGA)膀胱癌队列分析未接受ICB患者的亚型与结局关系。
  • 利用IMvigor210和TCGA队列的平行RNA测序数据分析亚型与免疫浸润和炎症的相关性。

主要发现

  • ARID1A突变、肿瘤突变负荷、瘤内异质性、免疫肽组非同义/同义突变比值(immune dN/dS)和肿瘤细胞纯度与ICB治疗后无进展生存和总生存相关。
  • 中性粒细胞与淋巴细胞比值和吸烟史与总生存呈负相关。
  • 上述遗传特征定义四种分子亚型,对ICB表现出差异化敏感性,并在IMvigor210队列中验证与临床获益相关。
  • 四种分子亚型在TCGA膀胱癌队列未接受ICB患者中亦与结局相关,但关系不同。
  • 在IMvigor210和TCGA队列中,亚型分别与免疫浸润和炎症相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients. METHODS: To reveal genetic variables associated with benefit from ICB, we performed whole-exome sequencing on tumor specimens from 88 patients with advanced bladder cancer treated with ICB. RESULTS: We identified several genetic factors that correlated with progression-free and overall survival after ICB therapy including ARID1A mutation, tumor mutational burden, intratumoral heterogeneity, the ratio of nonsynonymous to synonymous mutations in the immunopeptidome (immune dN/dS), and tumor cell purity. In addition, we noted that neutrophil-to-lymphocyte ratio and smoking history were negatively associated with overall survival. These genetic characteristics define four molecular subtypes demonstrating differential sensitivity to ICB. We validated the association of these four subtypes with clinical benefit from ICB in an independent cohort (IMvigor210). Finally, we showed that these molecular subtypes also correlate with outcome, although with distinct relationships, among patients not treated with ICB using The Cancer Genome Atlas (TCGA) bladder cancer cohort. Using parallel RNA sequencing data, the subtypes were also shown to correlate with immune infiltration and inflammation, respectively, in the IMvigor210 and TCGA cohorts. CONCLUSION: Together, our study defines molecular subgroups of bladder cancer that influence benefit from ICB.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sarfaty M, Golkaram M, Funt SA, et al. Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. J Clin Oncol. 2023. PMID: 36927002. doi:10.1200/JCO.22.02144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。